1. Home
  2. AAME vs MAIA Comparison

AAME vs MAIA Comparison

Compare AAME & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlantic American Corporation

AAME

Atlantic American Corporation

HOLD

Current Price

$2.90

Market Cap

51.0M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$2.08

Market Cap

49.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAME
MAIA
Founded
1968
2018
Country
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
49.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AAME
MAIA
Price
$2.90
$2.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.2K
1.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.25
$0.87
52 Week High
$3.71
$3.19

Technical Indicators

Market Signals
Indicator
AAME
MAIA
Relative Strength Index (RSI) 61.26 53.42
Support Level $2.51 $1.83
Resistance Level $2.64 $2.03
Average True Range (ATR) 0.13 0.23
MACD 0.02 -0.05
Stochastic Oscillator 95.28 36.45

Price Performance

Historical Comparison
AAME
MAIA

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: